A5100347246- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Lipoproteins and Cardiovascular Health
- Cardiac Imaging and Diagnostics
- Acute Ischemic Stroke Management
- Atherosclerosis and Cardiovascular Diseases
- Protease and Inhibitor Mechanisms
- Natural Products and Biological Research
- Adipokines, Inflammation, and Metabolic Diseases
- Antiplatelet Therapy and Cardiovascular Diseases
- Adrenal and Paraganglionic Tumors
- Pharmacology and Obesity Treatment
- Venous Thromboembolism Diagnosis and Management
- Cancer, Lipids, and Metabolism
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cardiovascular Function and Risk Factors
- Pituitary Gland Disorders and Treatments
- Peripheral Artery Disease Management
- Blood Coagulation and Thrombosis Mechanisms
- Cerebrovascular and Carotid Artery Diseases
- Fatty Acid Research and Health
- Inflammatory mediators and NSAID effects
- Hormonal Regulation and Hypertension
Chinese Academy of Medical Sciences & Peking Union Medical College
2005-2023
Anhui Medical University
2022
Fujian Medical University
2022
Anhui University
2022
Anhui University of Science and Technology
2022
First Affiliated Hospital of Zhengzhou University
2022
Bozhou People's Hospital
2022
Shandong University
2022
Zhengzhou Central Hospital
2022
Henan Provincial People's Hospital
2022
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been shown to be predictive of cardiovascular outcomes in stable coronary artery disease with diabetes. We aimed assess the relationship between PCSK9 and major adverse events (MACEs) ST-segment elevation myocardial infarction (STEMI) patients or without diabetes, as well relationships metabolism, inflammation platelet activation markers.A total 1027 STEMI undergoing primary percutaneous intervention (PCI) prior lipid-lowering therapy...
This study aimed to determine whether convertase subtilisin/kexin type 9 (PCSK9)-associated cardiovascular risk is modulated by triglyceride-glucose (TyG) in ST-segment elevation myocardial infarction (STEMI) patients with primary percutaneous coronary disease (PCI).A total of 1541 STEMI (aged ≥18 years) undergoing PCI were consecutively enrolled between March 2017 and 2019.When stratifying the overall population according TyG indices less than or greater median (TyG = 9.07) as well...
Coronary artery disease (CAD) can lead to left ventricular (LV) remodeling, which, in adverse cases, has been associated with heart failure and increased mortality. Here, we aimed evaluate the predictive value of noninvasive myocardial work index (NIMWI) for LV reverse remodeling patients multivessel CAD after percutaneous coronary intervention (PCI).A total 88 consecutive treated PCI were identified categorized according presence 3 months [≥15% decrease end diastolic volume (LVEDV)]. With...
Background. In vivo studies show that LL-37 inhibits the progression of atherosclerosis and predicts a lower risk recurrent ischemia in patients with acute myocardial infarction (AMI), which could be mediated by modulation lipid metabolism. The current study aimed to investigate effects various contents on prognostic impacts AMI. Methods. A total 1567 consecutive AMI were prospectively recruited from March 2017 January 2020. Patients firstly stratified into two groups median level then...
Total occlusion of the left main coronary artery (LMCA) is a rare but clinically serious event due to its poor prognosis. While bypass grafting (CABG) currently recommended for treatment these patients, recent studies support feasibility by percutaneous intervention (PCI). Here, we report diagnoses and two cases total LMCA. One patient presented with acute myocardial infarction complicated cardiogenic shock resulting from LMCA, other unstable angina pectoris chronic Both were successfully...
Background: As a specialized pro-resolving lipid mediator, resolvin D1 (RvD1) inhibits atherosclerosis progression in vivo by reducing regional oxidative stress and chronic inflammation. However, it is unclear how RvD1 involved human coronary artery disease. This study aims to investigate the association between plasma levels of culprit-plaque characteristics patients with ST-segment elevation myocardial infarction (STEMI). Methods: A total 240 STEMI undergoing optical coherence tomography...
Lidocaine has cardiovascular and neurologic toxicity, which is dose-dependent. Due to CYP3A4-involved metabolism, lidocaine may be prone drug-drug interactions.Given statins have the possibility of combination with in clinic, we established vitro models assess effect on metabolism lidocaine. Further pharmacokinetic alterations its main metabolite, monoethylglycinexylidide rats influenced by simvastatin, were investigated.In study revealed that among statins, had most significant inhibitory...
Culprit-plaque morphology [plaque rupture (PR) and plaque erosion (PE)] high-risk plaques (HRP) identified by optical coherence tomography (OCT) residual SYNTAX score (rSS) have been reported to influence clinical outcomes. Thus, in this study, we aimed investigate the prognostic implication of culprit-plaque rSS for major adverse cardiovascular events (MACE) patients with ST-segment elevation myocardial infarction (STEMI).
Background Previous studies reported the cardiac protection effect of preinfarction angina (PIA) in patients with acute myocardial infarction (AMI). We sought to identify culprit-plaque morphology and clinical outcomes associated PIA ST-segment elevation (STEMI) using optical coherence tomography (OCT). Methods Results A total 279 STEMI between March 2017 2019 who underwent intravascular OCT culprit lesion were prospectively included. Of them, 153 (54.8%) presented PIA. No differences...
The present study explored the predictive value of culprit high-risk plaque (HRP) detected by optical coherence tomography (OCT) for predicting major adverse cardiovascular events (MACEs) in patients with ST-segment elevation myocardial infarction (STEMI). HRP was defined as simultaneous presence four criteria: minimum lumen area <3.5 mm2, fibrous cap thickness <75 μm, lipid arc extension >180°, and macrophages. Patients (n = 274) were divided into non-HRP group 206) 68). MACEs a composite...
Objective: Different culprit plaque phenotypes including rupture (PR) and non-plaque (NPR), N-Terminal prohormone of brain natriuretic peptide (NT-proBNP) have been reported to influence clinical outcomes in patients with acute coronary syndrome (ACS). We aimed investigate the prognostic implication peak baseline values at admission for NT-proBNP major adverse cardiovascular events (MACE) ST-Segment Elevated Myocardial Infarction (STEMI) different phenotype. Methods: A total 428 STEMI...
Background: Apolipoprotein E-deficient (ApoE -/- ) mice are the most frequently used model of human atherosclerosis. Foam cells in mouse lesions have been believed to be primarily macrophage-derived using traditional staining with macrophage markers. Recent studies indicated that smooth muscle (SMCs) comprise at least 50% foam coronary atherosclerosis, and express reduced levels ATP-binding cassette transporter A1 (ABCA1) when compared intimal leucocytes. Identification SMC-derived is...
Objective To compare surgical hybrid procedures (open thromboembolectomy/bypass,transluminal angioplasty/stenting) and endovascular (percutaneous mechanical thrombectomy,catheter-directed intra-arterial thrombolysis,transluminal in patients with acute lower limb ischemia.Methods From June 2011 to 2012,the clinical data the six month follow-up of (less than 14 days) ischemia were collected analyzed,who have underwent modality (endovascular group)or surgery (surgery group).The combined...
Abstract Aims To compare the clinical outcomes between Double Kissing Mini-culotte stenting (DKMC) and (MC) in treating patients with true coronary bifurcation lesions (CBLs) real world. Methods This retrospective observational cohort study included 180 consecutive CBLs (Medina type 1,1,1; 1,0,1; 0,1,1). All eligible underwent angiography percutaneous intervention (PCI) two-stent techniques our hospital, among whom 97 received DKMC treatment (DKMC group) 83 MC treatment. The primary...